The invention relates to pyridone amide compounds of formula I and I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels: ##STR00001## The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

This invention provides a compound that is 4,4-(4-Carboxy)-4-nonyloxy-[1,1-biphenyl]-3,5-diyl)dibutanoic acid (CNBDA), derivative compounds of CNBDA, and pharmaceutical compositions thereof. The derivative compounds of CNBDA have one or more of the following substitutions (a) replacement of one or both of the carboxylic acid groups of the CNBDA compound with an organic acid group having 1-3, or 5-30, or more carbon atoms in chain length, wherein the carbon atom chains are either saturated, partially saturated, or unsaturated with respect to the carbon to carbon bonding, (b) replacement of the carboxylic groups of (a) with a phosphate, a sulphate, an amide, a hydroxyl, an aldehyde, or a halide group, and (c) replacement of the nonane group with an alkane having a carbon chain length of 1-8 or 10-30, or more carbon atoms. A method of treating a patient having cancer is provided.

Metal-organic framework material (MOF), comprising at least one metal center and at least one organic compound selected among the compounds according to formula (I):

##STR00001##

wherein n is from 1 to 2, R is (CH.sub.2CH.sub.2O).sub.mCH.sub.3 with m from 1 to 7; preferably when n=1, the two COOH groups are located in the para position relatively to the aryl substituted by the two RO groups; and preferably when n=2, the four COOH groups are located in the meta position relatively to the aryl substituted by the two RO groups.

Metal-organic framework material (MOF), comprising at least one metal center and at least one organic compound selected among the compounds according to formula (I):

##STR00001##

wherein n is from 1 to 2, R is (CH.sub.2CH.sub.2O).sub.mCH.sub.3 with m from 1 to 7; preferably when n=1, the two COOH groups are located in the para position relatively to the aryl substituted by the two RO groups; and preferably when n=2, the four COOH groups are located in the meta position relatively to the aryl substituted by the two RO groups.

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##

The present invention relates to therapeutic applications of aniline derivatives of formula (I), for example in treating glaucoma: Formula (I), R1a represents H, an halogen, a (C.sub.1-C.sub.6)alkyl or a CN; R1b represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R1c represents H or a (C.sub.1-C.sub.6)alkyl; R2 represents H, an halogen, an OH, an O(C.sub.1-C.sub.6)alkyl or (C.sub.1-C.sub.6)alkyl; R3 represents H, an halogen, a (C.sub.1-C.sub.6)alkyl, an OH, an O(C.sub.1-C.sub.6)alkyl, a CONH.sub.2 or CN; R4 represents H, an halogen or a (C.sub.1-C.sub.6)alkyl; R5 represents H or F: R7 represents H or F; R8 represents H or F; R9 represents H or (C.sub.1-C.sub.6)alkyl, or one of its enantiomers. ##STR00001##

The present invention comprises novel aromatic molecules, which can be used in the treatment of pathological conditions, such as cancer, skin diseases, muscle disorders, and immune system-related disorders such as disorders of the haematopoietic system including the haematologic system in human and veterinary medicine.

##STR00001##

Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and Plasmodium falciparum-induced inflammation.

##STR00001##

In Formula I, t is 0 or 1; q is 0 or 1; and r is 0, 1 or 2. R.sup.7 is hydrogen or alkyl having from 1 to 3 carbon atoms. R.sup.6 is hydrogen, hydroxy, halo, alkyl having from 1 to 3 carbon atoms, alkoxy having from 1 to 3 carbon atoms, nitro, thio, alkylthio, or cyano. X is C(O) or NH(R.sup.8) wherein R.sup.8 is hydrogen or alkyl having from 1 to 3 carbon atoms; provided that when X is C(O), r is 0 and t is 0. A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from halo, hydroxy, methyl, ethyl, perfluoromethyl, methoxy, ethoxy, perfluoromethoxy, nitro, and amino; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of Formula I by a ring carbon; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently monosubstituted by methyl or ethyl.

The invention relates to pyridone amide compounds of formula I and I or pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels:

##STR00001##

The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders, including pain.

A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group.